ArticleThe breast journal2026
Implementation and Audit of Mainstream Genetic Testing Within a High-Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion.
Article in The breast journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt is estimated that 5%-10% of patients who develop breast cancer have a causative inherited pathogenic or likely pathogenic variant (P/LP variant). In 2020, the UK National Test Directory published criteria for mainstream genetic testing for breast cancer patients (R208) and, subsequently, eligibility criteria to determine which patients are eligible for gene testing and PARP inhibitor treatment (R444.1).
methodsUsing the clearly defined criteria from NHS genomics, eligibility for testing under R208/R444.1 was determined for all patients diagnosed with breast cancer between March 2021 and March 2025. Eligible patients were offered genetic testing. Incidence of P/LP variants and impact on treatment were examined.
resultsA total of 1812 patients had new DCIS/invasive breast cancer diagnoses, 255 were eligible for testing and 196 consented. Of these, 28 patients (14.3%) had a P/LP variant. Eight of these patients were eligible only using family history criteria. Twenty-one patients were eligible for breast conservation surgery. Preoperative genetic results were available for 13: eight patients opted for bilateral mastectomy rather than breast conservation. Where results were available postoperatively, three of eight patients who had breast conservation are planning bilateral risk reducing surgery. Three women newly diagnosed with a BRCA variant received a PARP inhibitor. Eligibility assessment for testing was time-consuming for trained clinicians.
conclusion14.3% of patients eligible and tested for a breast cancer-related hereditary P/LP variant were positive, which aligns with the expected number predicted by Genomics England. Family history scoring is an important element. Positive results were associated with changes in surgical decision-making for 14 women and enabled 3 patients to receive a PARP inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.